2022
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma
Lozano AX, Chaudhuri AA, Nene A, Bacchiocchi A, Earland N, Vesely MD, Usmani A, Turner BE, Steen CB, Luca BA, Badri T, Gulati GS, Vahid MR, Khameneh F, Harris PK, Chen DY, Dhodapkar K, Sznol M, Halaban R, Newman AM. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nature Medicine 2022, 28: 353-362. PMID: 35027754, PMCID: PMC8866214, DOI: 10.1038/s41591-021-01623-z.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsImmune-related adverse eventsT-cell characteristicsIrAE developmentBlood samplesSevere immune-related adverse eventsAnti-PD-1 monotherapyCombination immune checkpoint inhibitorsT-cell receptor sequencingT cell abundanceCell receptor sequencingOrgan system involvementPeripheral blood samplesIrAE onsetCheckpoint inhibitorsAdverse eventsCheckpoint blockadeRNA sequencingTCR clonalityCombination therapyPatient cohortSystem involvementClinical managementTCR diversityImmunological state
2017
Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016
Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M. Future perspectives in melanoma research “Melanoma Bridge”, Napoli, November 30th–3rd December 2016. Journal Of Translational Medicine 2017, 15: 236. PMID: 29145885, PMCID: PMC5691855, DOI: 10.1186/s12967-017-1341-2.Peer-Reviewed Original ResearchConceptsT-cell therapyCombination therapyMetastatic melanomaChemokine receptorsT cellsHoming capacitySurvival rateTumor-Infiltrating Lymphocyte TherapyStage IV melanoma patientsAdoptive T-cell therapyCell therapyBRAF inhibitor monotherapyImmune checkpoint blockersSetting of treatmentIdentification of patientsChimeric antigen receptorEfficient combination therapyEmpowerment of patientsOptimize treatment regimensDifferent therapeutic agentsMelanoma BridgeImmunotherapy agentsOutcome enhancementCheckpoint blockadeCheckpoint blockers
1997
Diminished TCR signaling in cutaneous T cell lymphoma is associated with decreased activities of Zap70, Syk and membrane-associated Csk
Fargnoli M, Edelson R, Berger C, Chimenti S, Couture C, Mustelin T, Halaban R. Diminished TCR signaling in cutaneous T cell lymphoma is associated with decreased activities of Zap70, Syk and membrane-associated Csk. Leukemia 1997, 11: 1338-1346. PMID: 9264390, DOI: 10.1038/sj.leu.2400745.Peer-Reviewed Original ResearchMeSH KeywordsAdultCSK Tyrosine-Protein KinaseEnzyme ActivationEnzyme PrecursorsHumansImmunophenotypingIntracellular Signaling Peptides and ProteinsLymphoma, T-Cell, CutaneousPhosphotyrosineProtein-Tyrosine KinasesReceptors, Antigen, T-CellSignal TransductionSkin NeoplasmsSrc-Family KinasesSyk KinaseT-LymphocytesZAP-70 Protein-Tyrosine KinaseConceptsCutaneous T-cell lymphomaProtein tyrosine kinasesFunction of membersSignal transduction moleculesWeak mitogenic responseActivity of SykTCR ζ-chainCell surface receptorsTCR/CD3Membrane-bound fractionCellular proteinsTyrosyl phosphorylationT-cell lymphomaTyrosine phosphorylationTransduction moleculesLck kinaseTyrosine kinaseDistinct familiesΖ chainEffector moleculesKinaseSurface receptorsEnzymatic activityCell lymphomaNeoplastic cells